VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or
“RavenQuest”) – (CSE:RQB) is pleased to announce it has entered into a landmark research partnership
with Montreal’s McGill University, focussed upon three key issues facing the cannabis industry:
- Cannabis Cultivar Recognition & Identification
- Cannabis Plant Stabilization
- Cannabis Cultivation and Yield Improvements
The work will constitute a set of experiments that will increase scientific understanding of Cannabis genetics,
breeding and production and expand on existing scientific knowledge related to Cannabis, knowledge which is currently limited due
to long-term classification of Cannabis as a controlled substance.
The work will be conducted through collaboration between two McGill laboratories (one focussed on genetics and
one on crop yields) and will include the esteemed Dr. Donald Smith, who has patented technologies for improvement of crop yields.
When commenting on the project, Dr. Smith stated, “Plants, like humans, always have an associated community of microbes, and it
seems certain that the composition of this community affects the overall growth of cannabis plants and also their cannabinoid
profile. It will be key to have the correct microbial associations and to be able to beneficially manage their effects on
cannabis plants, to produce effective and consistent material.”
“In 2018, Canada will become only the second country in the world to legalize recreational cannabis. Safety
starts with understanding the genetic/genomic basis of plant productivity and this partnership will contribute to build this
knowledge,” says Mark Ware, Director of the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and Associate
Professor of Family Medicine and Anesthesia at McGill University.
The work includes a wide range of activities, from genetics to crop productivity and quality assurance, as well
as increased cannabinoid concentrations and enhanced yield of Cannabis. The work will also focus on the performance of
“Orbital Gardens” and their potentially significant and positive effect on crop yields.
“As the medical and retail markets for Cannabis grow, new scientific knowledge needs to be developed especially
given the very limited knowledge that exists since Cannabis has been listed as a controlled substance for many decades.
Furthermore, industrial Cannabis producers need to develop methods to produce genetically consistent, biologically stable
pharmaceutical quality products that will be provided for clinicians conducting medical research trials,” stated the Company’s CEO,
George Robinson.
Knowledge from this project will help the Company to expand its commercial activities based upon production
method advancements, as well as obtain Plant Breeder’s Rights for newly developed cultivars. All knowledge gained through the
partnership project will be transferred to the Company for (1) commercial products and (2) use in industrial medical marijuana
production systems. This will strengthen the company and promote wider industrial consideration of the “Orbital Garden”
system and biocontrol methods for powdery mildew control and regulation of cannabinoid concentrations, both of which are becoming
major considerations for regulators and producers as the industry matures.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized research & development.
For further details on the Company readers are referred to the Company's web site (www.rqbglobal.com) and its Canadian regulatory filings on SEDAR at www.sedar.com.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
"George Robinson"
Chief Executive Officer
For further information, please contact: Mathieu McDonald, Corporate Communications 1-877-282-1586
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been
prepared by management.
Cautionary Note Regarding Forward-Looking Statements
All statements in this press release, other than statements of historical fact, are "forward-looking
information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the
development of a licensed cannabis production facility and anticipated production from such a facility. The Company provides
forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and
readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to
inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those
identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company
has attempted to identify important factors that could cause actual actions, events or results to differ materially from those
described in forward-looking information, there may be other factors that cause actions, events or results not to be as
anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and
future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation
to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless
required by law.
